| Keywords: |
immunohistochemistry; cancer survival; treatment response; overall survival; thalidomide; clinical trial; drug tolerability; review; squamous cell carcinoma; bevacizumab; cisplatin; erlotinib; fluorouracil; drug efficacy; monotherapy; treatment duration; unspecified side effect; clinical trials as topic; gemcitabine; paclitaxel; temozolomide; positron emission tomography; follow up; cancer palliative therapy; adenocarcinoma; carboplatin; metastasis; computer assisted tomography; etoposide; combination chemotherapy; calcium; creatinine; calcium blood level; creatinine blood level; practice guideline; carcinogenesis; docetaxel; irinotecan; neuroendocrine tumor; chromosome aberration; practice guidelines as topic; thorax radiography; platinum derivative; physical examination; cancer of unknown primary site; liver function test; urinalysis; radioimmunotherapy; primary health care; neoplasms, unknown primary; occult cancer; proton therapy; thoracocentesis; paracentesis
|
